Effect of Early Versus Late Surgical Intercostal Block on Postoperative Pain Relief Following Video-Assisted Thoracic Surgery (VATS)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasme University Hospital

About this trial

Video-assisted thoracoscopic surgery (VATS) is associated with significant postoperative pain despite lower morbidity compared with thoracotomy. Adequate pain management is essential within Enhanced Recovery After Surgery (ERAS) pathways to preserve respiratory function and facilitate postoperative recovery. Surgical intercostal block performed under direct vision is a simple and effective regional analgesic technique commonly used following VATS. However, the optimal timing of intercostal block administration during surgery remains uncertain.

This prospective randomized double-blind study will compare surgical intercostal block performed at the beginning versus the end of the surgical procedure. The study aims to evaluate the effect of block timing on postoperative pain intensity and postoperative opioid consumption. The results may help optimize multimodal analgesic strategies in patients undergoing thoracic surgery.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Scheduled for single-port or two-port video-assisted thoracoscopic surgery (VATS).

ASA classification 1 to 3

Able to understand the study, describe their pain and provide valid informed consent

Disqualifiers

Neurological or psychiatric conditions that compromise the reliable assessment of pain(dementia, cognitive impairment, severe communication disorders)

Chronic opioid use or regular use (> 3 months) of strong analgesics for chronic pain

History of allergy or known hypersensitivity to local anaesthetics

Coagulopathy or anticoagulant therapy precluding the safe performance of an intercostal block

Trial design

Treatments tested in this trial

  • Intercostal nerve block before (ropivacaine 0.375%)
  • Intercostal Nerve Bloc before (physiological serum)
  • ICNB after (ropivacaine 0.375%)
  • ICNB after (physiological serum)

Treatment groups

140 Participants
are divided into 2 treatment groups

Sponsors and collaborators